Stopping Wegovy for 2 weeks: the reality behind the myth

The myth: two weeks off won't make much difference

This is the most common misunderstanding our prescribers hear. Because Wegovy is a once-weekly injection with a relatively long half-life (roughly a week) people assume the medicine is still working for a good while after the last dose. That is partly true. Blood levels of semaglutide do decline gradually rather than dropping off a cliff. The NHS patient information for semaglutide notes that effects are tied to sustained dosing, not a single injection.

What actually happens is more nuanced. The pharmacological half-life extends the tail, but your appetite-regulating effects track the drug concentration. By the end of the first week without an injection, many people notice hunger returning with more urgency. By the end of a second week, the central satiety signalling that made smaller portions feel satisfying has diminished considerably. Gastric emptying (the slowing that helps you feel full for longer) also picks back up. So the practical experience of two weeks off is often more disruptive than the pharmacology alone would suggest.

That gap matters especially if you are mid-titration. Miss two doses at 1mg, and you are not simply pausing at 1mg; you are reintroducing the medicine into a system that has partly readjusted. If you have been reading about what two weeks on Wegovy typically looks like, you will notice the contrast, the early weeks are when the medicine is actively recalibrating your hunger signals.

What actually happens when you stop for a fortnight

Clinically, a two-week break falls into a grey zone. It is long enough for appetite to rebound meaningfully, but short enough that it would not typically affect your overall eligibility or medical history. The more practical concern is what happens when you restart.

Resuming at your previous dose after two or more missed injections is not automatically safe. Some people tolerate it without difficulty; others experience a recurrence of nausea, vomiting or digestive discomfort that was much milder during the original titration. The reason is straightforward: your gut has partly re-sensitised to the medicine. Restarting as though nothing happened can feel like beginning the first weeks all over again, which is uncomfortable and sometimes leads people to abandon treatment prematurely.

This is why the NHS England guidance on weight-management injections and the prescribing information both recommend discussing any break with your clinical team before resuming. The prescriber may suggest dropping back a dose level for a week or two before returning to where you were. There is no universal rule; the right approach depends on how long you were off and how well you tolerated each dose previously. One practical habit worth building: before your next scheduled injection, check the date on your pen and the date of your last injection side by side, if the gap is approaching or past two weeks, that is the moment to contact your prescriber rather than inject and hope for the best.

For those curious about shorter gaps, our page on stopping Wegovy for a week covers the distinct considerations that apply to a single missed dose.

When a planned break might be unavoidable

Life does not always cooperate with a weekly injection schedule. Surgery, illness, travel to regions without cold-chain storage, or a temporary supply issue can all force a pause. If you know a break is coming, the single most useful thing to do is flag it early with whoever prescribes your treatment. That conversation takes minutes and can prevent a difficult restart.

Supply has been a real issue in recent years. If a gap is driven by availability rather than choice, it is worth knowing that where you source Wegovy matters considerably, pharmacies operating through the licensed UK supply chain are far better placed to manage stock consistently than unverified online sellers. Any seller offering these medicines without a prescription and a clinical assessment is operating outside UK law; the MHRA has issued repeated warnings about counterfeit and illegally traded semaglutide pens circulating online.

Pregnancy, breastfeeding, or actively trying to conceive are circumstances where Wegovy should be stopped and not restarted without explicit clinical guidance. Under-18s are not a licensed population. These are absolute considerations, not scheduling questions; they sit outside the two-week framing entirely and require a direct conversation with your GP or prescriber.

If you are interested in how the medicine builds over time, the pages covering six weeks on Wegovy and four weeks on Wegovy give a clearer picture of what the cumulative effect looks like when treatment continues uninterrupted.

Restarting: what a responsible prescriber will want to know

When you return to treatment after a fortnight off, expect your prescribing team to ask a few specific questions: how many doses you missed, whether you experienced any rebound symptoms during the gap, your current weight, and whether anything changed medically in the meantime. These are not procedural hoops. Each one helps the prescriber decide whether to continue at your current dose or step back temporarily.

At nume, a clinician reviews your case before every repeat order, not as a formality, but because the clinical picture does shift. If your gap has been two weeks or longer, that context is part of the review. You can find more about how our team approaches ongoing prescribing on the clinical team page, or explore the broader question of how semaglutide works for weight management. For anyone weighing up whether treatment is right for them at this stage, our weight-loss treatment overview sets out what the options look like side by side.

A two-week pause is not catastrophic. But it is not neutral either. Handled with clinical input, it is manageable. Handled without it, it is the point where a lot of people quietly give up on treatment that was otherwise working. If you are ready to get started with a proper assessment, you can begin your free consultation with our prescribers today.